Published in Protein Sci on April 01, 2009
Insight into amyloid structure using chemical probes. Chem Biol Drug Des (2011) 1.10
Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One (2010) 1.06
Molecular dynamics simulations of Ibuprofen binding to Abeta peptides. Biophys J (2009) 0.91
Disordered binding of small molecules to Aβ(12-28). J Biol Chem (2011) 0.90
Flexibility and binding affinity in protein-ligand, protein-protein and multi-component protein interactions: limitations of current computational approaches. J R Soc Interface (2011) 0.86
Resveratrol inhibits the formation of multiple-layered β-sheet oligomers of the human islet amyloid polypeptide segment 22-27. Biophys J (2011) 0.85
Anthraquinone-2-sulfonic acid (AQ2S) is a novel neurotherapeutic agent. Cell Death Dis (2013) 0.85
Binding of nonsteroidal anti-inflammatory drugs to Abeta fibril. Proteins (2010) 0.85
Alzheimer's protective A2T mutation changes the conformational landscape of the Aβ₁₋₄₂ monomer differently than does the A2V mutation. Biophys J (2015) 0.84
Molecular dynamics simulations of anti-aggregation effect of ibuprofen. Biophys J (2010) 0.83
Effects of several quinones on insulin aggregation. Sci Rep (2014) 0.82
The role of molecular simulations in the development of inhibitors of amyloid β-peptide aggregation for the treatment of Alzheimer's disease. ACS Chem Neurosci (2012) 0.82
Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr Med Chem (2015) 0.81
Potential synergy between tau aggregation inhibitors and tau chaperone modulators. Alzheimers Res Ther (2013) 0.80
Naproxen interferes with the assembly of Aβ oligomers implicated in Alzheimer's disease. Biophys J (2011) 0.79
Interaction of amyloid inhibitor proteins with amyloid beta peptides: insight from molecular dynamics simulations. PLoS One (2014) 0.77
Evidence of π-stacking interactions in the self-assembly of hIAPP(22-29). Proteins (2013) 0.77
Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors. J Comput Aided Mol Des (2010) 0.76
Targeted studies on the interaction of nicotine and morin molecules with amyloid β-protein. J Mol Model (2014) 0.75
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci (1993) 7.92
Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed Engl (2003) 5.63
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature (2006) 3.76
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Dissecting the assembly of Abeta16-22 amyloid peptides into antiparallel beta sheets. Structure (2003) 3.18
Stabilities and conformations of Alzheimer's beta -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects. Proc Natl Acad Sci U S A (2002) 3.06
Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. J Mol Biol (2004) 3.05
Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem (1996) 2.93
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28
Evaluation of a fast implicit solvent model for molecular dynamics simulations. Proteins (2002) 2.27
Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res (2004) 2.23
The role of side-chain interactions in the early steps of aggregation: Molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35. Proc Natl Acad Sci U S A (2003) 2.14
Molecular dynamics simulations of Alzheimer's beta-amyloid protofilaments. J Mol Biol (2005) 1.99
Direct observation of Abeta amyloid fibril growth and inhibition. J Mol Biol (2004) 1.82
Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci (2005) 1.80
Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput Biol (2007) 1.71
Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem (2004) 1.62
Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry (2004) 1.60
Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol (2006) 1.58
Replica exchange molecular dynamics simulations of amyloid peptide aggregation. J Chem Phys (2004) 1.53
Kinetic control of dimer structure formation in amyloid fibrillogenesis. Proc Natl Acad Sci U S A (2004) 1.52
Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death. Biochemistry (2008) 1.32
Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging (2006) 1.30
Computational models for the prediction of polypeptide aggregation propensity. Curr Opin Chem Biol (2006) 1.25
N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry (2006) 1.22
A molecular dynamics approach to the structural characterization of amyloid aggregation. J Mol Biol (2006) 1.16
IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl (2007) 1.11
Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem (2007) 1.10
Small-molecule inhibitors of islet amyloid polypeptide fibril formation. Angew Chem Int Ed Engl (2008) 1.09
Pathways and intermediates of amyloid fibril formation. J Mol Biol (2007) 1.06
Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J (1997) 1.04
Hydrophobic cooperativity as a mechanism for amyloid nucleation. J Mol Biol (2007) 1.04
Sequence dependence of amyloid fibril formation: insights from molecular dynamics simulations. J Mol Biol (2005) 1.04
Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed Engl (2009) 1.03
New insights into the mechanism of Alzheimer amyloid-beta fibrillogenesis inhibition by N-methylated peptides. Biophys J (2007) 1.02
Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry (2006) 1.01
Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid. FEBS Lett (2005) 1.01
Structures of soluble amyloid oligomers from computer simulations. Proteins (2006) 0.95
CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. Electrophoresis (2009) 0.88
Inhibition of amyloid fibrillation of lysozyme by indole derivatives--possible mechanism of action. FEBS J (2007) 0.88
Insights into stability and toxicity of amyloid-like oligomers by replica exchange molecular dynamics analyses. Biophys J (2008) 0.87
Inhibition of amyloid fibrillization of hen egg-white lysozymes by rifampicin and p-benzoquinone. Biotechnol Prog (2007) 0.81
Anion-pi interactions in cyanuric acids: a combined crystallographic and computational study. Chemistry (2005) 0.81
Electrostatic interaction of pi-acidic amides with hydrogen-bond acceptors. Bioorg Med Chem Lett (2003) 0.79
Trimethyl isocyanurate and triethyl isocyanurate. Acta Crystallogr C (1998) 0.76
The protein folding network. J Mol Biol (2004) 2.63
Evaluation of a fast implicit solvent model for molecular dynamics simulations. Proteins (2002) 2.27
The role of side-chain interactions in the early steps of aggregation: Molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35. Proc Natl Acad Sci U S A (2003) 2.14
The robustness of pollination networks to the loss of species and interactions: a quantitative approach incorporating pollinator behaviour. Ecol Lett (2010) 2.10
Wordom: a program for efficient analysis of molecular dynamics simulations. Bioinformatics (2007) 2.05
Predicting free energy changes using structural ensembles. Nat Methods (2009) 1.93
Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci (2005) 1.80
FACTS: Fast analytical continuum treatment of solvation. J Comput Chem (2008) 1.79
Local modularity measure for network clusterizations. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 1.72
PARP1 ADP-ribosylates lysine residues of the core histone tails. Nucleic Acids Res (2010) 1.64
Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol (2006) 1.58
Molecular dynamics simulations of protein folding from the transition state. Proc Natl Acad Sci U S A (2002) 1.51
The role of aromaticity, exposed surface, and dipole moment in determining protein aggregation rates. Protein Sci (2004) 1.50
New insights into the folding of a β-sheet miniprotein in a reduced space of collective hydrogen bond variables: application to a hydrodynamic analysis of the folding flow. J Phys Chem B (2013) 1.48
Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases. Nat Struct Mol Biol (2013) 1.47
Quantum mechanical methods for drug design. Curr Top Med Chem (2010) 1.45
Phi-value analysis by molecular dynamics simulations of reversible folding. Proc Natl Acad Sci U S A (2005) 1.35
Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. J Mol Biol (2007) 1.33
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics (2009) 1.32
Wordom: a user-friendly program for the analysis of molecular structures, trajectories, and free energy surfaces. J Comput Chem (2010) 1.31
Alpha-Helix folding in the presence of structural constraints. Proc Natl Acad Sci U S A (2008) 1.30
Membrane localization and flexibility of a lipidated ras peptide studied by molecular dynamics simulations. J Am Chem Soc (2004) 1.27
The free energy landscape of small molecule unbinding. PLoS Comput Biol (2011) 1.25
The folding and dimerization of HIV-1 protease: evidence for a stable monomer from simulations. J Mol Biol (2004) 1.22
One-dimensional barrier-preserving free-energy projections of a beta-sheet miniprotein: new insights into the folding process. J Phys Chem B (2008) 1.21
Kinetic analysis of molecular dynamics simulations reveals changes in the denatured state and switch of folding pathways upon single-point mutation of a beta-sheet miniprotein. Proteins (2008) 1.20
Weak temperature dependence of the free energy surface and folding pathways of structured peptides. Proteins (2002) 1.18
Analysis of the distributed computing approach applied to the folding of a small beta peptide. Proc Natl Acad Sci U S A (2003) 1.13
Efficient modularity optimization by multistep greedy algorithm and vertex mover refinement. Phys Rev E Stat Nonlin Soft Matter Phys (2008) 1.10
The chromodomain of LIKE HETEROCHROMATIN PROTEIN 1 is essential for H3K27me3 binding and function during Arabidopsis development. PLoS One (2009) 1.10
Functional plasticity in the substrate binding site of beta-secretase. Structure (2005) 1.07
Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One (2010) 1.06
Efficient evaluation of binding free energy using continuum electrostatics solvation. J Med Chem (2004) 1.06
Pathways and intermediates of amyloid fibril formation. J Mol Biol (2007) 1.06
Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. J Med Chem (2005) 1.05
Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat Chem Biol (2012) 1.05
Amyloid aggregation on lipid bilayers and its impact on membrane permeability. J Mol Biol (2008) 1.05
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes. J Med Chem (2002) 1.03
A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem (2009) 1.03
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem (2007) 1.03
Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem (2009) 1.03
Estimation of protein folding probability from equilibrium simulations. J Chem Phys (2005) 1.02
Delineation of folding pathways of a β-sheet miniprotein. J Phys Chem B (2011) 1.01
Ser170 controls the conformational multiplicity of the loop 166-175 in prion proteins: implication for conversion and species barrier. FASEB J (2007) 1.01
Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. PLoS Negl Trop Dis (2009) 1.01
Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors. Proteins (2008) 1.01
In silico discovery of beta-secretase inhibitors. J Am Chem Soc (2006) 1.01
Micelle-like architecture of the monomer ensemble of Alzheimer's amyloid-β peptide in aqueous solution and its implications for Aβ aggregation. J Mol Biol (2010) 1.00
Epigenetic mechanisms regulate stage differentiation in the minimized protozoan Giardia lamblia. Mol Microbiol (2010) 0.99
2D-IR study of a photoswitchable isotope-labeled alpha-helix. J Phys Chem B (2010) 0.96
Design, synthesis and biological evaluation of indane-2-arylhydrazinylmethylene-1,3-diones and indol-2-aryldiazenylmethylene-3-ones as beta-amyloid aggregation inhibitors. Eur J Med Chem (2009) 0.96
Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. J Med Chem (2006) 0.95
High-throughput virtual screening using quantum mechanical probes: discovery of selective kinase inhibitors. ChemMedChem (2010) 0.95
Organism complexity anti-correlates with proteomic beta-aggregation propensity. Protein Sci (2005) 0.94
Fast protein folding on downhill energy landscape. Protein Sci (2003) 0.94
Fragment-based de novo ligand design by multiobjective evolutionary optimization. J Chem Inf Model (2008) 0.94
Spontaneous formation of detergent micelles around the outer membrane protein OmpX. Biophys J (2005) 0.94
Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein. J Med Chem (2011) 0.94
Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments. J Mol Biol (2007) 0.94
Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem (2004) 0.92
Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J Med Chem (2006) 0.92
Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. J Med Chem (2009) 0.91
Amyloid fibril polymorphism is under kinetic control. J Am Chem Soc (2010) 0.91
Disordered binding of small molecules to Aβ(12-28). J Biol Chem (2011) 0.90
Is quantum mechanics necessary for predicting binding free energy? J Med Chem (2008) 0.90
Kinetic response of a photoperturbed allosteric protein. Proc Natl Acad Sci U S A (2013) 0.89
Automated docking of highly flexible ligands by genetic algorithms: a critical assessment. J Comput Chem (2004) 0.89
Equilibrium distribution from distributed computing (simulations of protein folding). J Phys Chem B (2011) 0.89
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities. Eur J Med Chem (2010) 0.89
A gain-of-function mutation of Arabidopsis cryptochrome1 promotes flowering. Plant Physiol (2010) 0.88
CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. Electrophoresis (2009) 0.88
Calculation of protein ionization equilibria with conformational sampling: pK(a) of a model leucine zipper, GCN4 and barnase. Proteins (2002) 0.88
Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Toxicol Appl Pharmacol (2012) 0.88
Improving quantitative structure-activity relationships through multiobjective optimization. J Chem Inf Model (2009) 0.88
Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. J Med Chem (2008) 0.87
Change of the unbinding mechanism upon a mutation: a molecular dynamics study of an antibody-hapten complex. Protein Sci (2005) 0.87
Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem (2011) 0.86
Library screening by fragment-based docking. J Mol Recognit (2010) 0.86
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography. J Med Chem (2012) 0.85
Computational analysis of the S. cerevisiae proteome reveals the function and cellular localization of the least and most amyloidogenic proteins. Proteins (2007) 0.85
Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups. J Chem Inf Model (2007) 0.85
Dynamics in the active site of β-secretase: a network analysis of atomistic simulations. Biochemistry (2011) 0.85
Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring. ChemMedChem (2009) 0.85
Optimization of designed armadillo repeat proteins by molecular dynamics simulations and NMR spectroscopy. Protein Sci (2012) 0.84
Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics. ChemMedChem (2012) 0.84
QSAR and QSPR studies of a highly structured physicochemical domain. J Chem Inf Model (2006) 0.83
Modeling of proteins and their assemblies with the Integrative Modeling Platform. Methods Mol Biol (2014) 0.83
Carnosine inhibits Aβ(42) aggregation by perturbing the H-bond network in and around the central hydrophobic cluster. Chembiochem (2013) 0.83